NCT03830450 (AKIrisk) is a clinical trial in Acute Kidney Injury (Nontraumatic), sponsored by Nikola Bradic, MD.

Who is sponsoring NCT03830450?

NCT03830450 is sponsored by Nikola Bradic, MD.

What condition does NCT03830450 study?

NCT03830450 studies Acute Kidney Injury (Nontraumatic).

Is NCT03830450 still recruiting?

NCT03830450 is currently status unknown. Last updated 13 November 2020.

Last reviewed 2020-11-13 · How we verify

NCT03830450: AKIrisk

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers of Acute Kidney Injury in Cardiac Surgery

Status unknown Last updated 13 November 2020

What this trial tests

trial in Acute Kidney Injury (Nontraumatic) in 50 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Nikola Bradic, MD
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 December 2020
Primary completion	31 December 2022
Estimated completion	31 December 2022

Conditions studied

Acute Kidney Injury (Nontraumatic) — all drugs for Acute Kidney Injury (Nontraumatic) →

Sponsor

Nikola Bradic, MD

Who can join

Adults 18 to 80, any sex, with Acute Kidney Injury (Nontraumatic). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute kidney injury (AKI) is the most common complication in patients after cardiac surgery. An usual estimation of risk for AKI is estimation of serum creatinine, which is unreliable indicator of AKI risk. Because of that, today different biomarkers are investigated to predict incidence for development AKI after cardiac surgery. This investigation will try to find potentially risk patients for developing AKI after cardiac surgery by using conventional markers (creatinine, glomerular filtration rate) in perioperative period comparing with two different biomarkers neutrophil gelatinase-associated lipocalin (NGAL) and growth differentiation factor 15 (GDF-15) which are proven markers in patients with increased risk for AKI development.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.
Asaf S, Maqsood F, Jalil J, Sarfraz Z, et al · · 2023 · cited 38× · PMID 36529828 · DOI 10.1007/s12026-022-09352-2

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury (Nontraumatic)

Currently open trials in the same condition.

NCT07447791 — WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients · NA · recruiting
NCT06259760 — AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03830450 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nikola Bradic, MD
Last refreshed: 13 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03830450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing